ライフサイエンスコーパス: interleukin-4 receptor

1 interleukin-13 genes (IL4 and IL13) with the interleukin-4 receptor A gene (IL4RA), contributing to t

2 The signaling function of mutant interleukin-4 receptor a was examined by flow cytometry,

3 IL4R encodes a subunit of the interleukin-4 receptor, a molecule critical to T-helper

4 n gamma (IFN-gamma) receptor (IFN-gammaR) or interleukin 4 receptor alpha (IL-4Ralpha) were infected

5 Previous studies comparing interleukin 4 receptor alpha (IL-4Ralpha)(-/-) and inter

6 rleukin 2 receptor gamma chain (IL2ry)-, and interleukin 4 receptor alpha (IL4Ra)-knockout mice, but

7 Focal demyelination in mice lacking IL4I1 or interleukin 4 receptor alpha (IL4Ralpha) results in incr

8 reg) cells in a manner that was dependent on interleukin-4 receptor alpha (IL-4Ralpha) expression in

9 ion, and we demonstrated a role for enhanced interleukin-4 receptor alpha (IL-4Ralpha) expression on

10 Here, we investigate Interleukin-4 receptor alpha (IL-4Ralpha) into which the

11 Interleukin-4 receptor alpha (IL-4Ralpha) signaling is r

12 rophage conversion required both T cells and interleukin-4 receptor alpha (IL-4Ralpha) signaling.

13 ully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Ralpha) subunit, demon

14 monstrated that, during skin repair in mice, interleukin-4 receptor alpha (IL-4Ralpha)-dependent macr

15 ous studies have suggested that mutations in interleukin-4 receptor alpha (IL4Ralpha) are associated

16 A novel interleukin-4 receptor alpha allele was identified in wh

17 Polymorphisms in the interleukin-4 receptor alpha chain (IL-4R alpha) have be

18 r and activation of transcription 6 (Stat6), interleukin-4 receptor alpha chain (IL-4Ralpha), or IL-4

19 inical improvement of AD that is mediated by interleukin-4 receptor alpha inhibition and the subseque

20 The R576 allele of interleukin-4 receptor alpha is strongly associated with

21 Dupilumab, a fully human anti-interleukin-4 receptor alpha monoclonal antibody, inhibi

22 576 (R576) in the cytoplasmic domain of the interleukin-4 receptor alpha protein.

23 Dupilumab is a fully human antibody to interleukin-4 receptor alpha that improves the signs and

24 Interleukin-4 receptor-alpha (IL-4Ralpha) mediates the i

25 ergy expenditure in wild-type, Ucp1(-/-) and interleukin-4 receptor-alpha double-negative (Il4ra(-/-)

26 Moreover, the interleukin-4 receptor-alpha genotype of airway smooth m

27 Interleukin-4 receptor-alpha was identified as a novel p

28 Dupilumab (an anti-interleukin-4-receptor-alpha monoclonal antibody) blocks

29 s dependent on type 2 adaptive immunity, the interleukin-4 receptor, and recruitment of C-C chemokine

30 resses the interleukin-1 receptor, CD206 and interleukin-4 receptor, but not CD163.

31 nition of the phosphopeptides of insulin and interleukin-4 receptors by the IRS-1 PTB domain is predo

32 involved in PH etiology, PH still occurs in interleukin-4 receptor-deficient mice under these condit

33 e has been identified in the promoter of the interleukin-4 receptor gene, and STAT6 is shown to be in

34 ) of antibodies that specifically engage the interleukin-4 receptor heterodimer.

35 d to have higher degradation efficacy to the interleukin 4 receptor (IL-4R) compared to traditional i

36 The interleukin 4 receptor (IL-4R) is a central mediator of

37 We found that interleukin 4 receptor (IL-4R) knockout and downstream s

38 been approved: the biologics dupilumab (anti-interleukin-4 receptor (IL-4R) alpha in 2017), tralokinu

39 om IIP patients based on their expression of interleukin-4 receptor (IL-4R) and IL-13R subunits.

40 susceptible (Il4ra(F709)) mice with enhanced interleukin-4 receptor (IL-4R) signaling exhibited STAT6

41 s long been established that dimerization of Interleukin-4 receptor (IL-4R) subunits is a pivotal ste

42 To target interleukin-4 receptor (IL-4R), we used a recombinant pr

43 cer tissue samples express a high density of interleukin-4 receptor (IL-4R), whereas normal ovarian t

44 man glioblastoma cells express high affinity interleukin-4 receptor (IL-4R), which is an attractive t

45 ted domain of the alpha-subunit of the human interleukin-4 receptor (IL-4Ralpha).

46 We have identified interleukin-4 receptors (IL-4R) on human malignant astro

47 lines express high levels of plasma membrane interleukin-4 receptors (IL-4R).

48 ulation of interleukin-1 receptor 1 (IL1r1), interleukin-4 receptor (IL4r), fibroblast growth factor

49 oclonal antibody to the alpha subunit of the interleukin-4 receptor, in patients with persistent, mod

50 s that are required for both DNA binding and interleukin-4 receptor interaction, as well as residues

51 s been demonstrated to be a component of the interleukin-4 receptor, it is not required for specific

52 We discuss interleukin 4 receptor pathways, which recently have bee

53 8 to 0.65; P=0.001; FDR, P=0.07) and an I50V interleukin-4 receptor polymorphism (OR, 0.66; 95% CI, 0

54 sine-phosphorylated peptide derived from the interleukin-4 receptor signaling chain.

55 ensitization, this response was dependent on interleukin-4 receptor signaling.

56 cytokine signature and required steady-state interleukin-4 receptor signaling.

57 ogous reporter gene construct containing the interleukin-4 receptor STAT6 binding site.

58 n M2 but not M1 Msmall ef, Cyrillic required interleukin-4 receptor/Stat6.

59 Biologics targeting interleukin-4 receptor subunit alpha (IL-4Ralpha) and in

60 y be dependent on target availability of the interleukin-4 receptor subunit alpha, with an interpatie

61 inants governing the assembly of the type II interleukin-4 receptor, taking advantage of various agon

62 arched for mutations in the a subunit of the interleukin-4 receptor that would predispose persons to

63 rejection, whereas untransfected tumors and interleukin-4 receptor transfectant controls were reject

64 pressing both miRNAs and a peptide targeting interleukin-4 receptor, which is highly expressed in bre